812 related articles for article (PubMed ID: 30423294)
1. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells.
Jones CL; Stevens BM; D'Alessandro A; Reisz JA; Culp-Hill R; Nemkov T; Pei S; Khan N; Adane B; Ye H; Krug A; Reinhold D; Smith C; DeGregori J; Pollyea DA; Jordan CT
Cancer Cell; 2018 Nov; 34(5):724-740.e4. PubMed ID: 30423294
[TBL] [Abstract][Full Text] [Related]
2. Can we selectively target AML stem cells?
Jordan CT
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101100. PubMed ID: 31779978
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.
Pollyea DA; Stevens BM; Jones CL; Winters A; Pei S; Minhajuddin M; D'Alessandro A; Culp-Hill R; Riemondy KA; Gillen AE; Hesselberth JR; Abbott D; Schatz D; Gutman JA; Purev E; Smith C; Jordan CT
Nat Med; 2018 Dec; 24(12):1859-1866. PubMed ID: 30420752
[TBL] [Abstract][Full Text] [Related]
4. Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells.
Jones CL; Stevens BM; Pollyea DA; Culp-Hill R; Reisz JA; Nemkov T; Gehrke S; Gamboni F; Krug A; Winters A; Pei S; Gustafson A; Ye H; Inguva A; Amaya M; Minhajuddin M; Abbott D; Becker MW; DeGregori J; Smith CA; D'Alessandro A; Jordan CT
Cell Stem Cell; 2020 Nov; 27(5):748-764.e4. PubMed ID: 32822582
[TBL] [Abstract][Full Text] [Related]
5. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
Buettner R; Nguyen LXT; Morales C; Chen MH; Wu X; Chen LS; Hoang DH; Hernandez Vargas S; Pullarkat V; Gandhi V; Marcucci G; Rosen ST
J Hematol Oncol; 2021 Apr; 14(1):70. PubMed ID: 33902674
[TBL] [Abstract][Full Text] [Related]
6. Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
Sharma P; Pollyea DA
Curr Hematol Malig Rep; 2018 Aug; 13(4):256-264. PubMed ID: 29982865
[TBL] [Abstract][Full Text] [Related]
7. AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia.
Grenier A; Poulain L; Mondesir J; Jacquel A; Bosc C; Stuani L; Mouche S; Larrue C; Sahal A; Birsen R; Ghesquier V; Decroocq J; Mazed F; Lambert M; Andrianteranagna M; Viollet B; Auberger P; Lane AA; Sujobert P; Bouscary D; Sarry JE; Tamburini J
Cell Rep; 2022 Jan; 38(1):110197. PubMed ID: 34986346
[TBL] [Abstract][Full Text] [Related]
8. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
Jacque N; Ronchetti AM; Larrue C; Meunier G; Birsen R; Willems L; Saland E; Decroocq J; Maciel TT; Lambert M; Poulain L; Hospital MA; Sujobert P; Joseph L; Chapuis N; Lacombe C; Moura IC; Demo S; Sarry JE; Recher C; Mayeux P; Tamburini J; Bouscary D
Blood; 2015 Sep; 126(11):1346-56. PubMed ID: 26186940
[TBL] [Abstract][Full Text] [Related]
9. CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia.
He L; Arnold C; Thoma J; Rohde C; Kholmatov M; Garg S; Hsiao CC; Viol L; Zhang K; Sun R; Schmidt C; Janssen M; MacRae T; Huber K; Thiede C; Hébert J; Sauvageau G; Spratte J; Fluhr H; Aust G; Müller-Tidow C; Niehrs C; Pereira G; Hamann J; Tanaka M; Zaugg JB; Pabst C
EMBO Mol Med; 2022 Apr; 14(4):e14990. PubMed ID: 35253392
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells.
Stevens BM; Jones CL; Pollyea DA; Culp-Hill R; D'Alessandro A; Winters A; Krug A; Abbott D; Goosman M; Pei S; Ye H; Gillen AE; Becker MW; Savona MR; Smith C; Jordan CT
Nat Cancer; 2020 Dec; 1(12):1176-1187. PubMed ID: 33884374
[TBL] [Abstract][Full Text] [Related]
11. Extinguishing the Embers: Targeting AML Metabolism.
Culp-Hill R; D'Alessandro A; Pietras EM
Trends Mol Med; 2021 Apr; 27(4):332-344. PubMed ID: 33121874
[TBL] [Abstract][Full Text] [Related]
12. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.
Nechiporuk T; Kurtz SE; Nikolova O; Liu T; Jones CL; D'Alessandro A; Culp-Hill R; d'Almeida A; Joshi SK; Rosenberg M; Tognon CE; Danilov AV; Druker BJ; Chang BH; McWeeney SK; Tyner JW
Cancer Discov; 2019 Jul; 9(7):910-925. PubMed ID: 31048320
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Flexibility in Leukemia-Adapt or Die.
Nachmias B; Schimmer AD
Cancer Cell; 2018 Nov; 34(5):695-696. PubMed ID: 30423291
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response.
Sharon D; Cathelin S; Mirali S; Di Trani JM; Yanofsky DJ; Keon KA; Rubinstein JL; Schimmer AD; Ketela T; Chan SM
Sci Transl Med; 2019 Oct; 11(516):. PubMed ID: 31666400
[TBL] [Abstract][Full Text] [Related]
16. Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II.
Jones CL; Stevens BM; D'Alessandro A; Culp-Hill R; Reisz JA; Pei S; Gustafson A; Khan N; DeGregori J; Pollyea DA; Jordan CT
Blood; 2019 Jul; 134(4):389-394. PubMed ID: 31101624
[TBL] [Abstract][Full Text] [Related]
17. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.
Lagadinou ED; Sach A; Callahan K; Rossi RM; Neering SJ; Minhajuddin M; Ashton JM; Pei S; Grose V; O'Dwyer KM; Liesveld JL; Brookes PS; Becker MW; Jordan CT
Cell Stem Cell; 2013 Mar; 12(3):329-41. PubMed ID: 23333149
[TBL] [Abstract][Full Text] [Related]
18. Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML.
Karjalainen R; Liu M; Kumar A; He L; Malani D; Parsons A; Kontro M; Kallioniemi O; Porkka K; Heckman CA
Leukemia; 2019 Oct; 33(10):2548-2553. PubMed ID: 31175323
[No Abstract] [Full Text] [Related]
19. Simultaneous inhibition of Sirtuin 3 and cholesterol homeostasis targets acute myeloid leukemia stem cells by perturbing fatty acid β-oxidation and inducing lipotoxicity.
O'Brien C; Ling T; Berman JM; Culp-Hill R; Reisz JA; Rondeau V; Jahangiri S; St-Germain J; Macwan V; Astori A; Zeng A; Hong JY; Li M; Yang M; Jana S; Gamboni F; Tsao E; Liu W; Dick JE; Lin H; Melnick A; Tikhonova A; Arruda A; Minden MD; Raught B; D'Alessandro A; Jones CL
Haematologica; 2023 Sep; 108(9):2343-2357. PubMed ID: 37021547
[TBL] [Abstract][Full Text] [Related]
20. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
